raav2/8-hcyp4v2
Gene therapyexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Apr 21, 2021 (NCT04722107)
Timeline
Indications
Mechanism of action
- Cytochrome P450 4V2Supplementation
supplementation - CYP4V2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07307469 | N/A | Mar 31, 2026 | Government of China |
| NCT06743646 | Phase 3 | Dec 30, 2024 | Government of China |
| NCT05832684 | Phase 1/Phase 2 (Phase 2) | Feb 20, 2023 | Government of China, Tianjin Medical University |
| NCT05714904 | Early Phase 1 (Phase 1) | Sep 23, 2022 | Peking University |
| NCT04722107 | Early Phase 1 (Phase 1) | Apr 21, 2021 | Capital Medical University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 3 | 3 | 3 | 2023 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Tianjin Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1